|
KMID : 0360319950270040620
|
|
Journal of Korean Cancer Research Association
1995 Volume.27 No. 4 p.620 ~ p.629
|
|
|
A Phase II Study of VP-16, Ifosfamide, and Cisplatin(VIP) Combination Chemotherapy for Small Cell Lung Cancer
|
|
이록윤
박영석/한윤창/김호중/현인규/정기석/이정애/우인숙/박영이
|
|
|
Abstract
|
|
|
We conducted a phase Ⅱtrial combining etoposide(VP-16), ifosfamide(IFM), and cisplatin (DDP) in previously untreated patinet with histologically confirmed small cell lung cancer (SCLC). Each cycle consisted of VP-16 100mg/m* i.v. days 1-3, IFN
1,000mg/m* i.v. days 1-2 with mesna, and DDP 100mg/m* i.v. day 1. Cycles were repeated at 3 week intervals. Patients of limited SCLC received chest irradiation concurrently with the third cycle of VIP chemotherapy. Patients with complete
remission
received prophylactic cranial irradiation after the 6th cycle of chemotherapy.
Thirty-seven patients were enrolled. Ages ranged from 34 to 76(median 61 years); 32 were male, and 5 female. Nineteen patients had limited disease(LD) and 18 extensive disease(ED). Three patients were not evaluable because of lost to follow up(2
patients) and early death(1 patient). Of 34 evaluable patients, 13 patients( LD; 12, ED; 1) had complete remissions, 19 patients(LD; 6, ED; 13) had partial remissions and overall remission rate was 94%. The median remission duration was 8.6
months(LD;
12.5months, D; 5.1months). Disease free survival was 14.5 months in patients achieved complete remission. The median duration of follow-up was 21 months (1 to 39 months), and overall median survival was 12.8months(16.1 months for LD, 8.2 months
for
ED).
Hematologic side effects(WHO Gr≥2) of evaluable 168 cycles of chemotherapy were anemia in 10 occassions(6%), leukopenia in 35 occassions(21%), thrombocytopenia in 27 occassions(16%). Nonhematologic side effects(WHO Gr≥2) included alopecia(91%),
nausea
and vomiting (80%), peripheral neuropathies (31%), and stomatitis (11%).
In conclusion, VIP combination chemotherapy seems to be a safe, effective, and well-tolerated regimen in SCLC.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|